Back to search
FDAFDA · Food and drugs·Recall number D-1457-2016

Glipizide 2.5 mg Extended-release tablets, 30-count bottle, Rx Only, Manufactured By: Patheon Pharmaceuticals Inc Cincinnati, OH 45237, NDC 00591-0900-30

Published August 24, 2016 · Recall initiated: June 30, 2016

Summary

FDA records drug Class II recall D-1457-2016, published August 24, 2016 and initiated June 30, 2016. Recalling firm: Actavis Inc; Status: Terminated; Reported quantity: 167,152 bottles; Lot: Lot # 3132593, 3132594, 3134420, 3134421,3134422, Exp. 02/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Actavis Inc
Distributor
Nationwide
Lot
Lot # 3132593, 3132594, 3134420, 3134421,3134422, Exp. 02/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glipizide 2.5 mg Extended-release tablets, 30-count bottle, Rx Only, Manufactured By: Patheon Pharmaceuticals Inc Cincinnati, OH 45237, NDC 00591-0900-30 recalled?

Yes. FDA published recall D-1457-2016 on August 24, 2016. Reported hazard: Failed Dissolution Specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

What should I do if I have this product?

Voluntary: Firm initiated · Letter